期刊
PHARMACEUTICS
卷 13, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics13040483
关键词
antibody– drug conjugates; HER-3; targeted therapy; duocarmycin
资金
- AIRC [18467, 20043]
The ADC EV20/NMS-P945, developed by combining an anti-HER-3 antibody with a DNA alkylating agent, showed target-dependent cytotoxic activity against various tumor cells in vitro and therapeutic effectiveness in mouse xenograft tumor models. Pharmacokinetics and toxicological studies in monkeys indicated that this ADC is well tolerated and has favorable half-life and stability, supporting its further clinical development as a therapeutic agent for HER-3-expressing malignancies.
HER-3 is becoming an attractive target for antibody-drug conjugate (ADC)-based therapy. Indeed, this receptor and its ligands are found to be overexpressed in several malignancies, and re-activation of its downstream signaling axis is known to play a critical role in modulating the sensitivity of targeted therapeutics in different tumors. In this study, we generated a novel ADC named EV20/NMS-P945 by coupling the anti-HER-3 antibody EV20 with a duocarmycin-like derivative, the thienoindole (TEI) NMS-P528, a DNA minor groove alkylating agent through a peptidic cleavable linker. This ADC showed target-dependent cytotoxic activity in vitro on several tumor cell lines and therapeutic activity in mouse xenograft tumor models, including those originating from pancreatic, prostatic, head and neck, gastric and ovarian cancer cells and melanoma. Pharmacokinetics and toxicological studies in monkeys demonstrated that this ADC possesses a favorable terminal half-life and stability and it is well tolerated. These data support further EV20/NMS-P945 clinical development as a therapeutic agent against HER-3-expressing malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据